Illuminating the cross-talk between tumor metabolism and immunity in IDH-mutated cancers.
Journal
Current opinion in biotechnology
ISSN: 1879-0429
Titre abrégé: Curr Opin Biotechnol
Pays: England
ID NLM: 9100492
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
24
08
2020
revised:
16
11
2020
accepted:
30
11
2020
pubmed:
29
12
2020
medline:
29
6
2021
entrez:
28
12
2020
Statut:
ppublish
Résumé
Mutations in the genes encoding isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) are key drivers of diverse cancers, including gliomas and hematological malignancies. IDH mutations cause neomorphic enzymatic activity that results in the production of the oncometabolite 2-hydroxyglutarate (2-HG). In addition to 2-HG's well-known effects on tumor cells themselves, it has become increasingly clear that 2-HG directly influences the tumor microenvironment (TME). In particular, the non-cell-autonomous impact of 2-HG on the immune system likely plays a major role in shaping disease development and response to therapy. It is therefore critical to understand how IDH mutations affect the metabolism, epigenetics, and functions of tumor-infiltrating immune cells. Such knowledge may point towards new therapeutic approaches to treat IDH-mutant cancers.
Identifiants
pubmed: 33360716
pii: S0958-1669(20)30180-4
doi: 10.1016/j.copbio.2020.11.013
pii:
doi:
Substances chimiques
Isocitrate Dehydrogenase
EC 1.1.1.41
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
181-185Subventions
Organisme : CIHR
Pays : Canada
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.